Matthias Steger

Matthias Steger's long career in pharma and biotech began with F. Hoffmann-La Roche in 1999, when he worked in the design and synthesis of active molecules for a variety of therapeutic indications - next, he joined Axovan (later acquired by Actelion), where he built and implemented a new platform for orphan GPCR drug discovery - Matthias then branched out into investment banking at Kepler Equities before returning to Roche in 2007 - he became the firm’s global head of research and technology partnering, a role in which he investigated and managed more than 50 collaborations - in 2015 he followed his strong entrepreneurial instincts, first establishing SequelBlu, an independent advisory firm aimed at assisting companies with sustainable innovation, and then Endogena.

Matthias earned his MSc in organic chemistry and biochemistry at the University of Zurich, and his Ph.D. in medicinal chemistry at the University of Sussex. In 2005 he completed an MBA at the University of St Gallen, where he was awarded Dean’s Honors.